Novel Yeast-based Strategy Unveils Antagonist Binding Regions on the Nuclear Xenobiotic Receptor PXR*

Background: Ketoconazole binds to and antagonizes pregnane X receptor (PXR) activation. Results: Yeast high throughput screens of PXR mutants define a unique region for ketoconazole binding. Conclusion: Ketoconazole genetically interacts with specific PXR surface residues. Significance: A yeast-based genetic method to discover novel nuclear receptor interactions with ligands that associate with surface binding sites is suggested. The pregnane X receptor (PXR) is a master regulator of xenobiotic metabolism, and its activity is critical toward understanding the pathophysiology of several diseases, including inflammation, cancer, and steatosis. Previous studies have demonstrated that ketoconazole binds to ligand-activated PXR and antagonizes receptor control of gene expression. Structure-function as well as computational docking analysis suggested a putative binding region containing critical charge clamp residues Gln-272, and Phe-264 on the AF-2 surface of PXR. To define the antagonist binding surface(s) of PXR, we developed a novel assay to identify key amino acid residues on PXR based on a yeast two-hybrid screen that examined mutant forms of PXR. This screen identified multiple “gain-of-function” mutants that were “resistant” to the PXR antagonist effects of ketoconazole. We then compared our screen results identifying key PXR residues to those predicted by computational methods. Of 15 potential or putative binding residues based on docking, we identified three residues in the yeast screen that were then systematically verified to functionally interact with ketoconazole using mammalian assays. Among the residues confirmed by our study was Ser-208, which is on the opposite side of the protein from the AF-2 region critical for receptor regulation. The identification of new locations for antagonist binding on the surface or buried in PXR indicates novel aspects to the mechanism of receptor antagonism. These results significantly expand our understanding of antagonist binding sites on the surface of PXR and suggest new avenues to regulate this receptor for clinical applications.

[1]  R. Stevenson,et al.  Jekyll and Hyde , 2013, Sir Frank Packer.

[2]  M. Redinbo,et al.  PXR antagonists and implication in drug metabolism , 2013, Drug metabolism reviews.

[3]  S. Mani,et al.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. , 2013, Cancer letters.

[4]  R. Fletterick,et al.  A conserved surface on the ligand binding domain of nuclear receptors for allosteric control , 2012, Molecular and Cellular Endocrinology.

[5]  E. Oetjen.  Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation , 2012 .

[6]  Scott A. Busby,et al.  Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation , 2011, Nature.

[7]  S. Mani,et al.  Post-translational modification of pregnane x receptor. , 2011, Pharmacological research.

[8]  S. Mani,et al.  In Vivo and In Vitro Characterization of a First-in-Class Novel Azole Analog That Targets Pregnane X Receptor Activation , 2011, Molecular Pharmacology.

[9]  R. Eglen,et al.  Drug discovery and the human kinome: recent trends. , 2011, Pharmacology & therapeutics.

[10]  S. Mani,et al.  Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. , 2011, Biochemical and biophysical research communications.

[11]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[12]  Taosheng Chen,et al.  Flavonoids activate pregnane × receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells , 2010, BMC Biochemistry.

[13]  N. Sharifi.  New agents and strategies for the hormonal treatment of castration-resistant prostate cancer , 2010, Expert opinion on investigational drugs.

[14]  J. Katzenellenbogen,et al.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). , 2010, Molecular endocrinology.

[15]  L. Pardo,et al.  Ligand-specific regulation of the extracellular surface of a G protein coupled receptor , 2009, Nature.

[16]  Sean Ekins,et al.  Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR , 2009, PLoS Comput. Biol..

[17]  M. Dwyer,et al.  Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists , 2009, Proceedings of the National Academy of Sciences.

[18]  A. Parent,et al.  Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. , 2009, ACS chemical biology.

[19]  Sean Ekins,et al.  Elucidating the ‘Jekyll and Hyde’ Nature of PXR: The Case for Discovering Antagonists or Allosteric Antagonists , 2009, Pharmaceutical Research.

[20]  Fangcao Lei.  Studying the Specificity of hPXR Antagonists Using a Panel of Cell-based Assays , 2009 .

[21]  G. Kalpana,et al.  Reverse two-hybrid screening to analyze protein-protein interaction of HIV-1 viral and cellular proteins. , 2009, Methods in molecular biology.

[22]  Sean Ekins,et al.  Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists , 2008, Molecular Pharmacology.

[23]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[24]  S. Mani,et al.  Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR). , 2008, Bioorganic & medicinal chemistry letters.

[25]  Feng Ding,et al.  Active Nuclear Receptors Exhibit Highly Correlated AF-2 Domain Motions , 2008, PLoS Comput. Biol..

[26]  K. Struhl,et al.  A nuclear receptor-like pathway regulating multidrug resistance in fungi , 2008, Nature.

[27]  L. Moore,et al.  The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. , 2008, Molecular endocrinology.

[28]  Dale J. Kempf,et al.  A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor , 2008, Drug Metabolism and Disposition.

[29]  Martha S. Head,et al.  Validation Studies of the Site-Directed Docking Program LibDock , 2007, J. Chem. Inf. Model..

[30]  Ji Young Kim,et al.  One- plus Two-hybrid System, a Novel Yeast Genetic Selection for Specific Missense Mutations Disrupting Protein/Protein Interactions* , 2007, Molecular & Cellular Proteomics.

[31]  Sean Ekins,et al.  Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites , 2007, Molecular Pharmacology.

[32]  Hao Li,et al.  Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs , 2007, Clinical Cancer Research.

[33]  Timothy M Willson,et al.  Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. , 2007, Bioorganic & medicinal chemistry.

[34]  Denise G. Teotico,et al.  Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole , 2007, Oncogene.

[35]  B. Blumberg,et al.  The Dietary Isothiocyanate Sulforaphane Is an Antagonist of the Human Steroid and Xenobiotic Nuclear Receptor , 2007, Molecular Pharmacology.

[36]  A. Conconi,et al.  High-throughput and sensitive assay to measure yeast cell growth: a bench protocol for testing genotoxic agents , 2006, Nature Protocols.

[37]  L. Moore,et al.  Human PXR forms a tryptophan zipper-mediated homodimer. , 2006, Biochemistry.

[38]  Sherif Abou Elela,et al.  A high-throughput method to measure the sensitivity of yeast cells to genotoxic agents in liquid cultures. , 2006, Mutation research.

[39]  M. Bard,et al.  Sterol synthesis and viability oferg11 (cytochrome P450 lanosterol demethylase) mutations inSaccharomyces cerevisiae andCandida albicans , 1993, Lipids.

[40]  S. Mani,et al.  Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents , 2005, Clinical Cancer Research.

[41]  M. Redinbo,et al.  Structure and function of the human nuclear xenobiotic receptor PXR. , 2005, Current drug metabolism.

[42]  E. Mellado,et al.  Targeted Gene Disruption of the 14-α Sterol Demethylase (cyp51A) in Aspergillus fumigatus and Its Role in Azole Drug Susceptibility , 2005, Antimicrobial Agents and Chemotherapy.

[43]  D. McDonnell,et al.  Androgen receptor-cofactor interactions as targets for new drug discovery. , 2005, Trends in pharmacological sciences.

[44]  H. Masuyama,et al.  The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. , 2005, Molecular endocrinology.

[45]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance in Candida albicans Biofilms: Phase-Specific Role of Efflux Pumps and Membrane Sterols , 2003, Infection and Immunity.

[46]  R. Prasad,et al.  Drug Susceptibilities of Yeast Cells Are Affected by Membrane Lipid Composition , 2002, Antimicrobial Agents and Chemotherapy.

[47]  Jonathan Chernoff,et al.  Detection of peptides, proteins, and drugs that selectively interact with protein targets. , 2002, Genome research.

[48]  A. Takeshita,et al.  Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of CYP3A4 Inhibition by Xenobiotics* , 2002, The Journal of Biological Chemistry.

[49]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[50]  K. Kuchler,et al.  The transmembrane domain 10 of the yeast Pdr5p ABC antifungal efflux pump determines both substrate specificity and inhibitor susceptibility , 2000, Molecular microbiology.

[51]  M. Ghannoum,et al.  Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance , 1999, Clinical Microbiology Reviews.

[52]  A. Bachhawat,et al.  The yeast multidrug resistance pump, Pdr5p, confers reduced drug resistance in erg mutants of Saccharomyces cerevisiae. , 1999, Microbiology.

[53]  W. Sabbagh,et al.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.

[54]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[55]  K. Kuchler,et al.  Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. , 1998, Molecular biology of the cell.

[56]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[57]  R. Haugland,et al.  Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts , 1997, Applied and environmental microbiology.

[58]  N. Gow,et al.  Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance , 1996, Antimicrobial agents and chemotherapy.

[59]  J. Swartz,et al.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.

[60]  S. Goff,et al.  Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[62]  O. Ozier-Kalogeropoulos,et al.  A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. , 1993, Nucleic acids research.